2Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, doubleblind, muhicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother, 2002, 46:451 -457.
3Colombo AL, Perfect J, DiNubile M, et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Micmhinl lnf~c.t Di~ 9f~i 99./170--/17/1.
4Garbino J, Lew D, Hirschel B, et al. Caspofungin in the treatment of oropharyngeal candidiasis. Int J Clin Pract, 2003, 57 : 143 - 144.
5Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol, 1994, 48:471 -497.
7Balani SK, Xu X, Arison BH, et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos, 2000, 28 : 1274 - 1278.
8Pfaller MA, Diekema DJ, Messer SA, et al. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp. , including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother, 2003, 47:1068- 1071.
9Ju JY, Polhamus C, Marr KA, et al. Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47 phox-/-knockout mice. Antimicrob Agents Chemother, 2002, 46: 1240-1245.
10Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin,itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol, 2003, 41:3623- 3626.
